Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Vitiligo
- Focus Proof of concept; Therapeutic Use
- 01 Aug 2017 Status changed from active, no longer recruiting to completed.
- 24 Apr 2017 Results from this trial will be presented at the 76th Annual Society for Investigative Dermatology Meeting, according to an Aclaris Therapeutics media release.
- 05 Apr 2017 Primary endpoint of percent change in Vitiligo Area Severity Index (VASI) score has been met, according to results published in the Journal of the American Academy of Dermatology.